Yiwei Zhao

Director, Analytical Development at Mural Oncology

Speaker

Yiwei Zhao currently serves as Director of Analytical Development at Mural Oncology, a spin-out company of Alkermes. Yiwei has been leading the group to develop, transfer, and validate analytical release assays and working with contract labs for release and stability testing activities focused on Mural’s late-stage pipeline. Yiwei also actively worked with stake holders to perform comparability studies to assess the impact caused from process step changes. Before Alkermes, Yiwei worked in Takeda, and ImmunoGen’'s analytical group, lead both company’s process-related impurity analytics program, majorly with HCP characterizations. Yiwei also served as USP expert panel member to co-author the HCP chapter.